Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
BioPharma Dive
The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the idiopathic and progressive forms of pulmonary fibrosis.
pharminent
April 30, 2026 (Last updated: April 30, 2026)
BioPharma Dive
The biotech will use the proceeds to develop inhalable versions of therapies already on the market for the idiopathic and progressive forms of pulmonary fibrosis.